H.C. Wainwright raised the firm’s price target on Kymera Therapeutics (KYMR) to $70 from $60 and keeps a Buy rating on the ...

Kymera Therapeutics (KYMR) has been analyzed by 4 analysts in the last three months, revealing a diverse range of ...

Kymera Therapeutics (KYMR) announced that results from the Phase 1 healthy volunteer clinical trial of KT-621, its first-in-class, oral STAT6 ...

Beyond its lead program, Kymera is also developing degraders for other immune and inflammatory diseases, including KT-579 for ...

Ratings for Kymera Therapeutics (NASDAQ:KYMR) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of ...

Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic ...

Kymera Therapeutics has announced the launch of a new program targeting the IRF5 transcription factor, enhancing its portfolio of oral immunology treatments for autoimmune and rheumatic diseases. The ...

WATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted ...

Citigroup began coverage on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $52.00 ...

WATERTOWN, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule ...

WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...